Mark G Foletta - Net Worth and Insider Trading

Mark G Foletta Net Worth

The estimated net worth of Mark G Foletta is at least $31 Million dollars as of 2024-04-25. Mark G Foletta is the Director of DexCom Inc and owns about 218,416 shares of DexCom Inc (DXCM) stock worth over $30 Million. Mark G Foletta is the Director of AMN Healthcare Services Inc and owns about 8,573 shares of AMN Healthcare Services Inc (AMN) stock worth over $482,231. Mark G Foletta is also the EVP & CFO of Tocagen Inc and owns about 1,003 shares of Tocagen Inc (TOCA) stock worth over $18,957. Besides these, Mark G Foletta also holds Regulus Therapeutics Inc (RGLS) . Details can be seen in Mark G Foletta's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark G Foletta has not made any transactions after 2024-02-29 and currently still holds the listed stock(s).

Transaction Summary of Mark G Foletta

To

Mark G Foletta Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark G Foletta owns 6 companies in total, including DexCom Inc (DXCM) , Enanta Pharmaceuticals Inc (ENTA) , and AMN Healthcare Services Inc (AMN) among others .

Click here to see the complete history of Mark G Foletta’s form 4 insider trades.

Insider Ownership Summary of Mark G Foletta

Ticker Comapny Transaction Date Type of Owner
DXCM DexCom Inc 2021-12-01 director
ENTA Enanta Pharmaceuticals Inc 2022-03-03 director
AMN AMN Healthcare Services Inc 2024-02-29 director
FBRX Forte Biosciences Inc 2017-04-12 EVP & Chief Financial Officer
RGLS Regulus Therapeutics Inc 2015-08-13 director
BIOCQ Biocept Inc 2015-08-18 Interim CFO

Mark G Foletta Latest Holdings Summary

Mark G Foletta currently owns a total of 4 stocks. Among these stocks, Mark G Foletta owns 218,416 shares of DexCom Inc (DXCM) as of December 1, 2021, with a value of $30 Million and a weighting of 98.36%. Mark G Foletta owns 8,573 shares of AMN Healthcare Services Inc (AMN) as of February 29, 2024, with a value of $482,231 and a weighting of 1.57%. Mark G Foletta also owns 1,003 shares of Tocagen Inc (TOCA) as of May 28, 2019, with a value of $18,957 and a weighting of 0.06%. The other 1 stocks Regulus Therapeutics Inc (RGLS) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Mark G Foletta

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DXCM DexCom Inc 2021-12-01 218,416 138.01 30,143,592
AMN AMN Healthcare Services Inc 2024-02-29 8,573 56.25 482,231
TOCA Tocagen Inc 2019-05-28 1,003 18.90 18,957
RGLS Regulus Therapeutics Inc 2015-08-13 83 2.27 188

Holding Weightings of Mark G Foletta


Mark G Foletta Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark G Foletta has made a total of 11 transactions in DexCom Inc (DXCM) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in DexCom Inc is the sale of 8,000 shares on December 1, 2021, which brought Mark G Foletta around $281,415.

According to the SEC Form 4 filings, Mark G Foletta has made a total of 4 transactions in AMN Healthcare Services Inc (AMN) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in AMN Healthcare Services Inc is the acquisition of 500 shares on February 29, 2024, which cost Mark G Foletta around $28,450.

According to the SEC Form 4 filings, Mark G Foletta has made a total of 1 transactions in Tocagen Inc (TOCA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tocagen Inc is the acquisition of 333 shares on May 28, 2019, which cost Mark G Foletta around $21,500.

More details on Mark G Foletta's insider transactions can be found in the Insider Trading History of Mark G Foletta table.

Insider Trading History of Mark G Foletta

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark G Foletta Trading Performance

GuruFocus tracks the stock performance after each of Mark G Foletta's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark G Foletta is -4.14%. GuruFocus also compares Mark G Foletta's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark G Foletta within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark G Foletta's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark G Foletta

Average Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 24.79 -4.14 -44.69 -48.77 -43.43 -62.47
Relative Return to S&P 500(%) 23.78 -6.13 -48.57 -58.14 -53.3 -71.35

Mark G Foletta Ownership Network

Ownership Network List of Mark G Foletta

No Data

Ownership Network Relation of Mark G Foletta


Mark G Foletta Owned Company Details

What does DexCom Inc do?

Who are the key executives at DexCom Inc?

Mark G Foletta is the director of DexCom Inc. Other key executives at DexCom Inc include * Matthew Vincent Dolan , EVP & Chief Legal Officer Micheal Jon Brown , and Chief Human Resources Officer Sadie Stern .

DexCom Inc (DXCM) Insider Trades Summary

Over the past 18 months, Mark G Foletta made no insider transaction in DexCom Inc (DXCM). Other recent insider transactions involving DexCom Inc (DXCM) include a net sale of 20,032 shares made by Steven Robert Pacelli , a net sale of 31,284 shares made by Sadie Stern , and a net sale of 329,692 shares made by Kevin R Sayer .

In summary, during the past 3 months, insiders sold 213,851 shares of DexCom Inc (DXCM) in total and bought 0 shares, with a net sale of 213,851 shares. During the past 18 months, 561,147 shares of DexCom Inc (DXCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 561,147 shares.

DexCom Inc (DXCM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

DexCom Inc Insider Transactions

No Available Data

Mark G Foletta Mailing Address

Above is the net worth, insider trading, and ownership report for Mark G Foletta. You might contact Mark G Foletta via mailing address: Amylin Pharmaceuticals Inc, 9360 Towne Centre Dr, San Diego Ca 92121.

Discussions on Mark G Foletta

No discussions yet.